HBK Sorce Advisory’s Intellia Therapeutics NTLA Stock Holding History

HBK Sorce Advisory’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,289	Closed	-$507K	–	596
2021 Q4	$507K	Sell	4,289 -135	-3%	-$16.9K	0.03%	324
2021 Q3	$593K	Sell	4,424 -46	-1%	-$6.96K	0.03%	294
2021 Q2	$724K	Buy	4,470 +1,976	+79%	+$154K	0.04%	254
2021 Q1	$200K	Buy	+2,494	New	+$167K	0.01%	513
2019 Q1	–	Sell	-10,367	Closed	-$142K	–	434
2018 Q4	$142K	Buy	10,367 +660	+7%	+$12.3K	0.02%	369
2018 Q3	$278K	Buy	9,707 +2,126	+28%	+$61.9K	0.03%	309
2018 Q2	$207K	Buy	+7,581	New	+$184K	0.02%	361

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

HBK Sorce Advisory's NTLA Position: Q1 2022 in Review

HBK Sorce Advisory sold out of Intellia Therapeutics (NTLA) in Q1 2022, closing a stake of 4,289 shares — an estimated $507K sold.

HBK Sorce Advisory first reported a position in NTLA in Q2 2018 and held it in 7 quarters. The position peaked at $724K in Q2 2021. 348 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

HBK Sorce Advisory reported no remaining Intellia Therapeutics position as of Q1 2022 after selling out during the quarter.
HBK Sorce Advisory sold 4,289 Intellia Therapeutics shares in Q1 2022, an estimated $507K.
HBK Sorce Advisory first reported a position in Intellia Therapeutics in Q2 2018 and held it in 7 quarters.
HBK Sorce Advisory's Intellia Therapeutics position peaked at $724K in Q2 2021.
348 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on HBK Sorce Advisory's 13F filing for Q1 2022, filed 13 May 2022.